title: Continuous venovenous hemodiafiltration for hyperlactatemia caused by telbivudine in a patient with chronic hepatitis B: a case report and update review.
abstract: Although there have been reports on telbivudine-induced myopathy and creatine kinase (CK) elevation, few reports focus on its effect on hyperlactatemia in patients with chronic hepatitis B (CHB). Here we reported a case of hyperlactatemia during telbivudine treatment. A 26-year-old Chinese man had been receiving telbivudine for CHB since July 2011, with a CK level of 68 U/L before the antiviral therapy. After 3 months he felt muscular weakness in both upper and lower extremities. A check in the local clinic found his CK level was increased to 222 U/L (upper limit of normal 170 U/L). However, he did not visit his doctor or stop the telbivudine treatment until he felt myalgia throughout his body. By this time his CK level had increased to 4151 U/L. Even after the withdrawal of telbivudine, his myalgia was exacerbated and his CK level was decreased extremely slowly. His constant myolysis developed into hyperlactatemia and he finally recovered after successful venovenous hemodiafiltration. The findings in this patient suggest that telbivudine may lead to high CK levels and hyperlactatemia may occur if telbivudine is not discontinued immediately when CK levels are clearly increased. Moreover, we emphasized that serum CK and lactate levels should be monitored closely during treatment with telbivudine in patients with CHB.
authors.affiliation: Department of Medical Intensive Care Unit, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, China.
authors.forename: Yan Hong
authors.initials: YH
authors.lastname: Wang
authors.forename: Ben Quan
authors.initials: BQ
authors.lastname: Wu
authors.forename: Hui
authors.initials: H
authors.lastname: Liu
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects*; D015415:Biomarkers / Q000097:blood; D003402:Creatine Kinase / Q000097:blood; D017583:Hemodiafiltration / Q000379:methods*; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D065906:Hyperlactatemia / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D008297:Male; D063806:Myalgia / Q000139:chemically induced; D000077712:Telbivudine; D013936:Thymidine / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D000998:Antiviral Agents; D015415:Biomarkers; D000077712:Telbivudine; D003402:Creatine Kinase; D013936:Thymidine
keywords: chronic hepatitis B; creatine kinase; hyperlactatemia; telbivudine